Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient

Stefan Glück, Carlos L. Arteaga, C. Kent Osborne

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.

Original languageEnglish (US)
Pages (from-to)5559-5561
Number of pages3
JournalClinical Cancer Research
Volume17
Issue number17
DOIs
StatePublished - Sep 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient'. Together they form a unique fingerprint.

  • Cite this